AAMU
BOLD

Amundi Asset Management US’s Audentes Therapeutics, Inc BOLD Stock Holding History

Amundi Asset Management US’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,300
Closed -$92 – 1712
2018
Q4 		$92 Buy
+4,300
New +$111K ﹤0.01% 1523
2018
Q1 		– Sell
-1,300
Closed -$41K – 1620
2017
Q4 		$41K Buy
+1,300
New +$35.7K ﹤0.01% 1519

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Amundi Asset Management US's BOLD Position: Q1 2019 in Review

Amundi Asset Management US sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2019, closing a stake of 4,300 shares — an estimated $92 sold.

Amundi Asset Management US first reported a position in BOLD in Q4 2017 and held it in 2 quarters. The position peaked at $41K in Q4 2017. 139 funds tracked by Wall St. Rank hold BOLD as of Q1 2019.

  • Amundi Asset Management US reported no remaining Audentes Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 4,300 Audentes Therapeutics, Inc shares in Q1 2019, an estimated $92.
  • Amundi Asset Management US first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 2 quarters.
  • Amundi Asset Management US's Audentes Therapeutics, Inc position peaked at $41K in Q4 2017.
  • 139 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2019.

Based on Amundi Asset Management US's 13F filing for Q1 2019, filed 13 May 2019.